Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study - Top-Institutions - MDSpire

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

  • By

  • Zhenghua Liu

  • Xinyu Wang

  • Jiayan Gai

  • Chen Wang

  • Xinlu Yi

  • Yufei Liu

  • Tao Zhou

  • June 26, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Fourth Hospital of Hebei Medical University
    Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei

    Key Differentiators

    • Oncology

  • #2

    North Central Cancer Treatment Group
    North Central Cancer Treatment Group

    Minneapolis, Minnesota

    Key Differentiators

    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    University of Padua
    University of Padua

    Padua, Italy

    Key Differentiators

    • Oncology

  • #5

    University Hospitals Leuven
    University Hospitals Leuven

    Leuven, Belgium

    Key Differentiators

    • Oncology

Original Source(s)

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

  • by Zhenghua Liu, Xinyu Wang, Jiayan Gai, Chen Wang, Xinlu Yi, Yufei Liu, Tao Zhou

  • June 26, 2026

Related Content

Rebuilding cancer care in post-conflict Syria: restoring continuity across the cancer care continuum

A systematic review and meta-analysis of the effects of walking training on cardiorespiratory fitness in cancer patients

Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors